Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR

被引：58

作者：

Oehler, V. G. ^{[1
]}

Qin, J. ^{[2
]}

Ramakrishnan, R. ^{[2
]}

Facer, G. ^{[2
]}

Ananthnarayan, S. ^{[3
,4
,5
]}

Cummings, C. ^{[1
]}

Deininger, M.

Shah, N. ^{[3
,4
,5
]}

McCormick, F. ^{[3
,4
,5
]}

Willis, S. ^{[6
]}

Daridon, A. ^{[2
]}

Unger, M. ^{[2
]}

Radich, J. P. ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

[2] Fluidigm Corp, San Francisco, CA USA

[3] UCSF Comprehens Canc Ctr, Div Hematol Oncol, San Francisco, CA USA

[4] UCSF Comprehens Canc Ctr, Dept Microbiol & Immunol, San Francisco, CA USA

[5] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA

[6] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA

来源：

LEUKEMIA | 2009年 / 23卷 / 02期

关键词：

IMATINIB; RESISTANCE;

D O I：

10.1038/leu.2008.183

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：396 / 399

页数：5

共 8 条

[1] Evaluating markers for the early detection of cancer: overview of study designs and methods [J].

Baker, SG ;

Kramer, BS ;

McIntosh, M ;

Patterson, BH ;

Shyr, Y ;

Skates, S .

CLINICAL TRIALS, 2006, 3 (01) :43-56

[2] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[3] Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations [J].

Branford, S ;

Rudzki, Z ;

Parkinson, I ;

Grigg, A ;

Taylor, K ;

Seymour, JF ;

Durrant, S ;

Browett, P ;

Schwarer, AP ;

Arthur, C ;

Catalano, J ;

Leahy, MF ;

Filshie, R ;

Bradstock, K ;

Herrmann, R ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2004, 104 (09) :2926-2932

[4] Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors [J].

Nardi, V. ;

Raz, T. ;

Cao, X. ;

Wu, C. J. ;

Stone, R. M. ;

Cortes, J. ;

Deininger, M. W. N. ;

Church, G. ;

Zhu, J. ;

Daley, G. Q. .

ONCOGENE, 2008, 27 (06) :775-782

[5] Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients:: a retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP) [J].

Nicolini, F. E. ;

Corm, S. ;

Le, Q. -H. ;

Sorel, N. ;

Hayette, S. ;

Bories, D. ;

Leguay, T. ;

Roy, L. ;

Giraudier, S. ;

Tulliez, M. ;

Facon, T. ;

Mahon, F. -X. ;

Cayuela, J. -M. ;

Rousselot, P. ;

Michallet, M. ;

Preudhomme, C. ;

Guilhot, F. ;

Roche-Lestienne, C. .

LEUKEMIA, 2006, 20 (06) :1061-1066

[6] Microfluidic digital PCR enables multigene analysis of individual environmental bacteria [J].

Ottesen, Elizabeth A. ;

Hong, Jong Wook ;

Quake, Stephen R. ;

Leadbetter, Jared R. .

SCIENCE, 2006, 314 (5804) :1464-1467

[7] ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia [J].

Soverini, S ;

Martinelli, G ;

Rosti, G ;

Bassi, S ;

Amabile, M ;

Poerio, A ;

Giannini, B ;

Trabacchi, E ;

Castagnetti, F ;

Testoni, N ;

Luatti, S ;

de Vivo, A ;

Cilloni, D ;

Izzo, B ;

Fava, M ;

Abruzzese, E ;

Alberti, D ;

Pane, F ;

Saglio, G ;

Baccarani, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4100-4109

[8] High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy [J].

Willis, SG ;

Lange, T ;

Demehri, S ;

Otto, S ;

Crossman, L ;

Niederwieser, D ;

Stoffregen, EP ;

McWeeney, S ;

Kovacs, I ;

Park, B ;

Druker, BJ ;

Deininger, MW .

BLOOD, 2005, 106 (06) :2128-2137

← 1 →